Organogenesis Holdings Overview
- Year Founded
-
1985
- Status
-
Public
- Employees
-
869
- Stock Symbol
-
ORGO
- Investments
-
5
- Share Price
-
$2.98
- (As of Monday Closing)
Organogenesis Holdings General Information
Description
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Contact Information
Website
www.organogenesis.comCorporate Office
- 85 Dan Road
- Canton, MA 02021
- United States
Corporate Office
- 85 Dan Road
- Canton, MA 02021
- United States
Organogenesis Holdings Stock Performance
As of 12-May-2025, Organogenesis Holdings’s stock price is $2.98. Its current market cap is $379M with 127M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.98 | $3.06 | $2.28 - $6.71 | $379M | 127M | 2.42M | -$0.16 |
Organogenesis Holdings Financials Summary
As of 31-Mar-2025, Organogenesis Holdings has a trailing 12-month revenue of $459M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 578,057 | 415,651 | 563,861 | 375,625 |
| Revenue | 458,760 | 482,043 | 433,140 | 450,893 |
| EBITDA | (6,839) | 15,763 | 27,948 | 33,019 |
| Net Income | (15,882) | 861 | 4,945 | 15,532 |
| Total Assets | 467,394 | 497,886 | 460,025 | 449,359 |
| Total Debt | 42,633 | 43,312 | 119,351 | 123,791 |
Organogenesis Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Organogenesis Holdings Comparisons
Industry
Financing
Details
Organogenesis Holdings Competitors (31)
One of Organogenesis Holdings’s 31 competitors is Mimedx, a Corporation company based in Marietta, GA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mimedx | Corporation | Marietta, GA | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Parexel International | Private Equity-Backed | Durham, NC | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ |
Organogenesis Holdings Patents
Organogenesis Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240024429-A1 | Porcine collagen compositions and methods of use thereof | Pending | 21-Jul-2021 | ||
| AU-2022316212-A1 | Porcine collagen compositions and methods of use thereof | Pending | 21-Jul-2021 | ||
| CA-3227151-A1 | Porcine collagen compositions and methods of use thereof | Pending | 21-Jul-2021 | ||
| EP-4373535-A2 | Porcine collagen compositions and methods of use thereof | Pending | 21-Jul-2021 | ||
| AU-2022242840-A1 | Methods kits and compositions for characterizing an anti-inflammatory response of a product | Pending | 23-Mar-2021 | G01N33/5073 |
Organogenesis Holdings Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Organogenesis Holdings Acquisitions (5)
Organogenesis Holdings’s most recent deal was a Merger/Acquisition with CPN Biosciences for . The deal was made on 17-Sep-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CPN Biosciences | 17-Sep-2020 | Merger/Acquisition | Medical Supplies | ||
| Avista Healthcare Public Acquisition | 10-Dec-2018 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| NuTech Medical | 24-Mar-2017 | Merger/Acquisition | Surgical Devices | ||
| Shire (Dermagraft business) | 17-Jan-2014 | Merger/Acquisition | Pharmaceuticals | ||
| NanoMatrix | 25-Feb-2008 | Merger/Acquisition | Biotechnology |
Organogenesis Holdings ESG
Risk Overview
Risk Rating
Updated September, 16, 2023
27.58 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Biotechnology
Subindustry
of 365
Rank
Percentile
Organogenesis Holdings Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| CPN Biosciences | Largo, FL |
Organogenesis Holdings FAQs
-
When was Organogenesis Holdings founded?
Organogenesis Holdings was founded in 1985.
-
Where is Organogenesis Holdings headquartered?
Organogenesis Holdings is headquartered in Canton, MA.
-
What is the size of Organogenesis Holdings?
Organogenesis Holdings has 869 total employees.
-
What industry is Organogenesis Holdings in?
Organogenesis Holdings’s primary industry is Biotechnology.
-
Is Organogenesis Holdings a private or public company?
Organogenesis Holdings is a Public company.
-
What is Organogenesis Holdings’s stock symbol?
The ticker symbol for Organogenesis Holdings is ORGO.
-
What is the current stock price of Organogenesis Holdings?
As of 12-May-2025 the stock price of Organogenesis Holdings is $2.98.
-
What is the current market cap of Organogenesis Holdings?
The current market capitalization of Organogenesis Holdings is $379M.
-
What is Organogenesis Holdings’s current revenue?
The trailing twelve month revenue for Organogenesis Holdings is $459M.
-
Who are Organogenesis Holdings’s competitors?
Mimedx, Mesoblast, AbbVie, Parexel International, and Bristol-Myers Squibb are some of the 31 competitors of Organogenesis Holdings.
-
What is Organogenesis Holdings’s annual earnings per share (EPS)?
Organogenesis Holdings’s EPS for 12 months was -$0.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
